Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: CARYTRE who wrote (1410)	2/10/1998 3:40:00 PM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

Cary, AutoCyte came out with news today and the market rejoiced; biz.yahoo.com Normal average trading volume on ACYT was 12,727 shares traded while today it is presently at 450,000 shares. Talk about investors turning on a dime! How does this new 44% one day increase (so far with about 20 minutes left to the close of trading) figure into your Fluff analysis? At the current new $6 price level for ACYT, I believe it (ACYT) would have a price/sales ratio of over 26. How does this new info translate into AccuMed's present price to sales and overall group numbers in your Fluff Analysis Model? In all fairness ACYT does have a much smaller share outstanding volume than ACMI. Frank